Level Four Advisory Services LLC Cuts Stock Holdings in Zoetis Inc. $ZTS

Level Four Advisory Services LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 50.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,188 shares of the company’s stock after selling 4,274 shares during the period. Level Four Advisory Services LLC’s holdings in Zoetis were worth $613,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Focus Partners Advisor Solutions LLC grew its holdings in Zoetis by 6.4% during the third quarter. Focus Partners Advisor Solutions LLC now owns 7,703 shares of the company’s stock worth $1,127,000 after acquiring an additional 460 shares during the period. Kingsview Wealth Management LLC lifted its holdings in Zoetis by 3.0% in the third quarter. Kingsview Wealth Management LLC now owns 9,546 shares of the company’s stock valued at $1,397,000 after acquiring an additional 277 shares during the period. Elo Mutual Pension Insurance Co lifted its holdings in Zoetis by 37.4% in the third quarter. Elo Mutual Pension Insurance Co now owns 44,185 shares of the company’s stock valued at $6,465,000 after acquiring an additional 12,032 shares during the period. WASHINGTON TRUST Co boosted its position in shares of Zoetis by 2.2% during the 3rd quarter. WASHINGTON TRUST Co now owns 72,911 shares of the company’s stock worth $10,668,000 after purchasing an additional 1,601 shares in the last quarter. Finally, Fairtree Asset Management Pty Ltd boosted its position in shares of Zoetis by 252.3% during the 3rd quarter. Fairtree Asset Management Pty Ltd now owns 16,071 shares of the company’s stock worth $2,352,000 after purchasing an additional 11,509 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.6%

Shares of Zoetis stock opened at $121.54 on Friday. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a 50 day moving average price of $126.06 and a 200 day moving average price of $133.20. The company has a market capitalization of $51.31 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.87 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. KeyCorp began coverage on shares of Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating for the company. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday. Finally, Barclays began coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.